公开(公告)号：US20230295179A1

公开(公告)日：2023-09-21

申请号：US18324616

申请日：2023-05-26

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. ERNST ,  Siegfried H. REICH ,  Paul A. SPRENGELER ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

CPC classification number: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.




For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20170145026A1

公开(公告)日：2017-05-25

申请号：US15358761

申请日：2016-11-22

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. ERNST ,  Siegfried H. REICH ,  Paul A. SPRENGELER ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D491/20 ,  C07D519/00 ,  C07D498/14 ,  C07D491/16 ,  C07D491/153 ,  C07D333/78 ,  C07D307/93

CPC classification number: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20180298017A1

公开(公告)日：2018-10-18

申请号：US15917973

申请日：2018-03-12

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. ERNST ,  Siegfried H. REICH ,  Paul A. SPRENGELER ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D519/00 ,  C07D333/78 ,  C07D307/93 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D491/153

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20230071483A1

公开(公告)日：2023-03-09

申请号：US17720529

申请日：2022-04-14

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. ERNST ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.